Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Ropidoxuridine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Shuttle Pharma Doses First Patients in Glioblastoma Trial
    Shuttle Pharma Doses First Patients in Glioblastoma Trial

    29 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/29/2970880/0/en/Shuttle-Pharma-Doses-First-Patients-in-Phase-2-Clinical-Trial-of-Ropidoxuridine-for-Treatment-of-Patients-with-Glioblastoma.html

    GLOBENEWSWIRE
    29 Oct 2024
    Share Share
    Shuttle Pharma Expands Trial For Glioblastoma Treatment
    Shuttle Pharma Expands Trial For Glioblastoma Treatment

    16 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/16/2946677/0/en/Shuttle-Pharma-Expands-Clinical-Trial-Site-Enrollment-for-Phase-2-of-Ropidoxuridine-for-Treatment-of-Patients-with-Glioblastoma.html

    GLOBENEWSWIRE
    16 Sep 2024
    Share Share
    Shuttle Pharma Provides Second Quarter 2024 Corporate Update
    Shuttle Pharma Provides Second Quarter 2024 Corporate Update

    04 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/04/2940918/0/en/Shuttle-Pharma-Provides-Second-Quarter-2024-Corporate-Update.html

    GLOBENEWSWIRE
    04 Sep 2024
    Share Share
    Plus Therapeutics Reports Q2 2024 Financial Results And Business Highlights
    Plus Therapeutics Reports Q2 2024 Financial Results And Business Highlights

    14 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/14/2930509/0/en/Plus-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Recent-Business-Highlights.html

    GLOBENEWSWIRE
    14 Aug 2024
    Share Share
    Shuttle Receives FDA Approval to Proceed with Phase II Trial of Ropidoxuridine
    Shuttle Receives FDA Approval to Proceed with Phase II Trial of Ropidoxuridine

    08 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/shuttle-pharmaceuticals-receives-fda-approval-to-proceed-with-phase-ii-clinical-trial-of-ropidoxuridine-for-treatment-of-patients-with-glioblastoma-302027844.html

    PR NEWSWIRE
    08 Jan 2024
    Share Share
    Shuttle Pharma Submits IND Application to the U.S. FDA for Ropidoxuridin
    Shuttle Pharma Submits IND Application to the U.S. FDA for Ropidoxuridin

    11 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/shuttle-pharmaceuticals-submits-ind-application-to-the-us-fda-for-ropidoxuridine-phase-ii-clinical-trial-for-patients-with-glioblastoma-302010823.html

    PR NEWSWIRE
    11 Dec 2023
    Share Share